Overview

LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
0
Participant gender:
All
Summary
The present study will recruit 50 symptomatic non-ischemic cardiomyopathy (NICM) patients with left ventricular ejection fraction (LVEF) below 35% and complete left bundle branch block (CLBBB), who have not received complete guideline-directed medical therapy (GDMT). Each patient was randomized to 2 groups, GDMT or left bundle branch pacing combined with GDMT (LBBP+GDMT) as initial therapy and was followed up for 2 phases: 0-6 months (phase I), 7-18 months (phase II). The primary objective is to compare the LVEF change , syncope and malignant ventricular arrhythmias between GDMT group and LBBP+GDMT group, and to observe which strategy will significantly reduce the percentage of recommendations for an implantable cardioverter-defibrillator (ICD) during phase I study. The second outcome measures including health economics, echocardiography parameters[left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV)], N-terminal pro B-type natriuretic peptide (NT-proBNP) level, New York Heart Association (NYHA) class, 6-minute walking distance (6MWD), quality of life score(QOL) and incidence of clinical adverse events.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborators:
Chinese Academy of Medical Sciences, Fuwai Hospital
First Affiliated Hospital of Wenzhou Medical University
Fujian Medical University Union Hospital
The First Affiliated Hospital of Dalian Medical University
West China Hospital
Criteria
Inclusion Criteria:

1. Non-ischemic cardiomyopathy with LVEF≤35% as assessed by echocardiography, NYHA class
II-III, and less than 3 months of optimized (complete) GDMT*;

2. Sinus rhythm (paroxysmal atrial fibrillation may be present) with complete left bundle
branch block meeting STRAUSS's criteria;

3. Between the ages of 18 and 80;

4. With informed consent signed.

Exclusion Criteria:

1. After mechanical tricuspid valve replacement;

2. Ischemic cardiomyopathy;

3. Persistent AF without AV node ablation;

4. History of unexplained syncope or indications for pacemaker implantation;

5. Indications for ICD implantation such as a history of sustained ventricular
tachycardia or sudden cardiac arrest;

6. Unstable angina, acute MI, CABG or PCI within the past 3 months;

7. Enrollment in any other study;

8. A life expectancy of less than 12 months;

9. Pregnant or with child-bearing potential;

10. History of heart transplantation.